"In the case of improvements to medicines that are innovations, this is justified. However, it appears that exclusivities are being granted where it is not justified," - @ChuckGrassley and @SenBillCassidy wrote in @NRO.
Show this thread
"That status quo frequently involves pharmaceutical companies’ making minor changes to existing drugs to gain additional market exclusivity, which keeps prices high." - @ChuckGrassley and @SenBillCassidyhttps://www.nationalreview.com/2019/10/prescription-drug-pricing-reduction-act-bipartisan-plan-make-prescription-drugs-affordable/ …
-
-
-
"The trick is to rein in gimmicks and abuses while maintaining incentives for true innovation that advances science. There must be a system that facilitates breakthrough treatments, but it needs to be sustainable for patients and taxpayers." -
@ChuckGrassley and@SenBillCassidyShow this thread
End of conversation
New conversation -
-
-
Rebates given to the pbm’s by the manufacturers keep prices high for patients and profits high for the pbm’s. It is sad that the pbm’s used threats of price increases on premiums and deductibles (and their lobbying money)to keep receiving those rebates.pic.twitter.com/xzN6xKjUXo
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Yes, then they bribe PBMs to get their meds on formulary. This is why USA prescription prices are the highest in the world. All at the expense of the American people.
@60Minutes@RIHouseofReps@RISenate@RIpharmacists@JimLangevin@davidcicilline@NBC10@wpri12@SenJackReed@NPRThanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.